Literature DB >> 10215629

A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development.

P Ducy1, M Starbuck, M Priemel, J Shen, G Pinero, V Geoffroy, M Amling, G Karsenty.   

Abstract

The molecular mechanisms controlling bone extracellular matrix (ECM) deposition by differentiated osteoblasts in postnatal life, called hereafter bone formation, are unknown. This contrasts with the growing knowledge about the genetic control of osteoblast differentiation during embryonic development. Cbfa1, a transcriptional activator of osteoblast differentiation during embryonic development, is also expressed in differentiated osteoblasts postnatally. The perinatal lethality occurring in Cbfa1-deficient mice has prevented so far the study of its function after birth. To determine if Cbfa1 plays a role during bone formation we generated transgenic mice overexpressing Cbfa1 DNA-binding domain (DeltaCbfa1) in differentiated osteoblasts only postnatally. DeltaCbfa1 has a higher affinity for DNA than Cbfa1 itself, has no transcriptional activity on its own, and can act in a dominant-negative manner in DNA cotransfection assays. DeltaCbfa1-expressing mice have a normal skeleton at birth but develop an osteopenic phenotype thereafter. Dynamic histomorphometric studies show that this phenotype is caused by a major decrease in the bone formation rate in the face of a normal number of osteoblasts thus indicating that once osteoblasts are differentiated Cbfa1 regulates their function. Molecular analyses reveal that the expression of the genes expressed in osteoblasts and encoding bone ECM proteins is nearly abolished in transgenic mice, and ex vivo assays demonstrated that DeltaCbfa1-expressing osteoblasts were less active than wild-type osteoblasts. We also show that Cbfa1 regulates positively the activity of its own promoter, which has the highest affinity Cbfa1-binding sites characterized. This study demonstrates that beyond its differentiation function Cbfa1 is the first transcriptional activator of bone formation identified to date and illustrates that developmentally important genes control physiological processes postnatally.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215629      PMCID: PMC316641          DOI: 10.1101/gad.13.8.1025

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  45 in total

1.  Mutational dysostosis (cleidocranial dysostosis).

Authors:  A B SOULE
Journal:  J Bone Joint Surg Am       Date:  1946-01       Impact factor: 5.284

2.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

3.  Limb development in mouse embryos. I. Analysis of teratogenic effects of retinoic acid.

Authors:  D M Kochhar
Journal:  Teratology       Date:  1973-06

Review 4.  Heritable diseases of collagen.

Authors:  D J Prockop; K I Kivirikko
Journal:  N Engl J Med       Date:  1984-08-09       Impact factor: 91.245

5.  Dynamic histomorphometry of alveolar bone remodeling in the adult rat.

Authors:  A Vignery; R Baron
Journal:  Anat Rec       Date:  1980-02

6.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo.

Authors:  J L Frendo; G Xiao; S Fuchs; R T Franceschi; G Karsenty; P Ducy
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

8.  Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfbeta.

Authors:  K Thirunavukkarasu; M Mahajan; K W McLarren; S Stifani; G Karsenty
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

9.  Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.

Authors:  S R Rittling; H N Matsumoto; M D McKee; A Nanci; X R An; K E Novick; A J Kowalski; M Noda; D T Denhardt
Journal:  J Bone Miner Res       Date:  1998-07       Impact factor: 6.741

10.  A Xenopus homologue of aml-1 reveals unexpected patterning mechanisms leading to the formation of embryonic blood.

Authors:  W D Tracey; M E Pepling; M E Horb; G H Thomsen; J P Gergen
Journal:  Development       Date:  1998-04       Impact factor: 6.868

View more
  206 in total

Review 1.  Regulation of osteoblast formation and function.

Authors:  J E Aubin
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.

Authors:  M Neale Weitzmann; Cristiana Roggia; Gianluca Toraldo; Louise Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Ectopic expression of SOX9 in osteoblasts alters bone mechanical properties.

Authors:  Bojian Liang; Meghan M Cotter; Dongxing Chen; Christopher J Hernandez; Guang Zhou
Journal:  Calcif Tissue Int       Date:  2011-12-06       Impact factor: 4.333

4.  Interactions between extracellular signal-regulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity.

Authors:  Chunxi Ge; Qian Yang; Guisheng Zhao; Hong Yu; Keith L Kirkwood; Renny T Franceschi
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

Review 5.  Building strong bones: molecular regulation of the osteoblast lineage.

Authors:  Fanxin Long
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

6.  Bio-Oss®acts on Stem cells derived from Peripheral Blood.

Authors:  Vincenzo Sollazzo; Annalisa Palmieri; Luca Scapoli; Marcella Martinelli; Ambra Girardi; Francesco Alviano; Agnese Pellati; Vittoria Perrotti; Francesco Carinci
Journal:  Oman Med J       Date:  2010-01

7.  Runx2 overexpression in bone marrow stromal cells accelerates bone formation in critical-sized femoral defects.

Authors:  Abigail M Wojtowicz; Kellie L Templeman; Dietmar W Hutmacher; Robert E Guldberg; Andrés J García
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

8.  High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage.

Authors:  Valérie Geoffroy; Michaela Kneissel; Brigitte Fournier; Alan Boyde; Patrick Matthias
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

9.  [Immunohistochemical study on collagen I content in the gingiva in cleidocranial dysplasia].

Authors:  Tobias Ach; Uwe Baumert; Christian Morsczeck; Regine Dahse; Torsten Eugen Reichert; Oliver Driemel
Journal:  Mund Kiefer Gesichtschir       Date:  2007-12

10.  Autophagy in osteoblasts is involved in mineralization and bone homeostasis.

Authors:  Marie Nollet; Sabine Santucci-Darmanin; Véronique Breuil; Rasha Al-Sahlanee; Chantal Cros; Majlinda Topi; David Momier; Michel Samson; Sophie Pagnotta; Laurence Cailleteau; Séverine Battaglia; Delphine Farlay; Romain Dacquin; Nicolas Barois; Pierre Jurdic; Georges Boivin; Dominique Heymann; Frank Lafont; Shi Shou Lu; David W Dempster; Georges F Carle; Valérie Pierrefite-Carle
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.